Elsilimomab

(Synonyms: B-E8; Anti-IL-6 MAB B-E8; Anti-Human IL6 Recombinant Antibody) 目录号 : GC69054

Elsilimomab (B-E8) 是一种抗白介素-6 (IL-6) 的 IgG1 单克隆抗体，其 KD 为 22 pM，IC50 为 1.4 nM。Elsilimomab 可用于多发性骨髓瘤、肾细胞癌和类风湿性关节炎 (RA) 的研究。

Cas No.:468715-71-1

规格	价格	库存	购买数量
5mg ¥9,450.00 现货 0 1 2 3 4 5 6 7 8 9 10 电话：400-920-5774 Email: sales@glpbio.cn 加 入 购 物 车 大 货 询 价				Customer Reviews Based on customer reviews. B1

Sample solution is provided at 25 µL, 10mM.

GlpBio产品文献引用

 

 

 

Nature
610.7931 (2022): 366-372

Nature
618, 1017–1023 (2023)

Cell
183.7 (2020): 1867-1883

Cell Research
31, 1291–1307 (2021)

Cell Research
33, 273–287 (2023)

Cell Research
33, 546–561 (2023)

Molecular Cancer
21.1 (2022): 1-17

Molecular Cancer
21.1 (2022): 1-18

Cancer Cell
39 (2021): 1-16

Cell Host Microbe
30.8 (2022): 1124-1138

Cell Host Microbe
31.5 (2023): 766-780

Cell Host Microbe
31.3 (2023): 418-43

Cell Metabolism
34.2 (2022): 240-255

Ann Rheum Dis
82(4): 533-545 (2023)

Cell Mol Immunol
20, 264–276 (2023)

Adv Funct Mater
33.35 (2023): 2214998

产品文档

Quality Control & SDS

View current batch: 1

Purity: >95.00%
• COA (Certificate Of Analysis)
• SDS (Safety Data Sheet)
• Datasheet

产品描述

Elsilimomab (B-E8) is a B9 cells were stimulated with human IL-6, which was effectively neutralized by antibody Elsilimomab.

[1]. Lee JJ, et al. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol Ther. 2014 Jul;22(7):1254-1265.
[2]. Burger R, et al. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica. 2017 Feb;102(2):381-390.
[3]. Finch DK, et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411(4):791-807.